Read more about Artificial intelligence could change future of antimicrobial drug discovery: Here's why on Devdiscourse ...

As China's new drug R&D enters the 'deep waters' of homogeneous competition, the path for followers has become increasingly ...

Iambic’s AI-platform includes Enchant, a multimodal transformer model designed to predict both preclinical and clinical endpoints, alongside NeuralPLexer. 1 Enchant recently received Nvidia HGX B200 ...

For patients taking medications that don't work as expected or pharmaceutical companies struggling with clinical trial ...

SPT Labtech, which designs and develops automated instrumentation and consumables for life sciences, and BellBrook Labs - a ...

The partnership aims to advance high-priority small molecule programmes using Iambic’s AI models and wet lab capabilities.

SPT Labtech, a global leader in the design and development of automated instrumentation and consumables for life sciences, and BellBrook Labs, a pioneer in high-throughput screening (HTS) assay tools, ...

To become a leader for humane technologies, India will need bold investments, global alliances, and strengthened participant ...

Synthace, the leader in software and services for assay development, today announced a collaboration with Charles River Laboratories International, Inc. (Charles River), a leading global drug ...

Fidelity International Discovery Fund gained 2.04% in Q4 2025, trailing its benchmark amid global market shifts. View the full portfolio and manager insights here.

Bitcoin miners pivoted their data centers to AI. But a less visible shift is happening from the bottom up, as crypto's GPU networks find a second life in AI inference.

Novel serotonergic agonists ("NSAs") are quickly becoming one of the more interesting stories in mental-health and ...